G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: Meta-analysis and pharmacoeconomic evaluation

Journal of Clinical Pharmacy and Therapeutics

Volumn 21, Issue 2, 1996, Pages 57-63

  Messori, A ^a   Trippoli, S ^a   Tendi, E ^a  

^a Geriatric Department   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEVER; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; COST-BENEFIT ANALYSIS; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; NEUTROPENIA;

EID: 0029894306     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1996.tb00001.x     Document Type: Article

References (24)

1. Frampton IE, Lee CR, Faulds D. (1994) Filgrastim - a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs, 48, 731-760.
2. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH. (1994) Incidence of neutropenic fever in patients treated with standard dose-combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte-colony-stimulating factor. Journal Clinical Oncology, 12, 1245-1250.
3. Mapelli V, Graf v.d. Schulenburg JM, Laaser U, Allhoff PG, Rossi F. (1994) Pharmacoeconomic evaluation of lenograstim: background, rationale, methodology and results. Pharmacoeconomics, 6(Suppl. 2), 27-35.
4. Glaspy JA, Jackway J. (1993) Cost considerations in therapy with myeloid growth factors. American Journal of Hospital Pharmacy, 50(Suppl. 3), 19-27.
5. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C, d'Albasio G, De Simone G, Martini N. (1994) Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disease: a meta-analysis. American Journal of Gastroenterology, 89, 692-698.
6. Messori A, Rampazzo R, Scroccaro G, et al. (1995) Effectiveness of gabexate mesilate in acute pancreatitis: a meta-analysis. Digestive Diseases and Sciences, 40, 734-738.
7. Miles DW, Fogarty O, Ash CM, et al. (1994) Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Journal Clinical Oncology, 12, 77-82.
8. Crawford J, Ozer H, Stroller R, et al. (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New England Journal of Medicine, 325, 164-170.
9. Woll J, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Tatcher N. (1995) Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenogastrim in small-cell lung cancer. Journal Clinical Oncology, 13, 652-659.
10. Trillet-Lenoir V, Green J, Manegold C, et al. (1993) Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. European Journal of Cancer, 29(A), 319-324.
11. Masuda N, Fukuoka M, Furuse K. (1992) CODE chemotherapy with or without recombinant human G-CSF in extensive stage small-cell lung cancer. Oncology, 42(Suppl. 1), 19-24.
12. Sacks HS, Berrier J, Reitman D, Ancona Bekr VA, Chalmers TC. (1987) Meta-analysis of randomized controlled trials. New England Journal of Medicine, 316, 450-455.
13. Mantel N, Haenzel W. (1959) Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22, 719-748.
14. Breslow NE, Day NE. (1987) Statistical Methods in Cancer Research. Vol. II. The Design and Analysis of Cohort Studies, pp. 109-120 IARC Scientific publications, Lyon, France.
15. Woolf B. (1955) On estimating the relation between blood group and disease. Annals of Human Genetics 9, 251-253.
16. Collins R, Yusuf S, Peto R. (1985) Overview of randomised trials of diuretics in pregnancy. British Medical Journal, 290, 17-25.
17. Laupacis A, Sackett DL, Roberts RS. (1988) An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine, 318, 1728-1733.
18. Simes RJ. (1987) Confronting publication bias: a cohort design for meta-analysis. Statistics in Medicine, 6, 11-29.
19. Cook DJ, Guyatt GH, Ryan G, et al. (1993) Should unpublished data be included in meta-analyses? Current convictions and controversies. Journal of the American Medical Association, 269, 2749-2753.
20. Rosenthal R. (1979) The 'file-drawer problem' and tolerance for null results. Psychological Bulletin. 86, 638-641.
21. Klein S, Simes J, Blackburn GL. (1986) Total parenteral nutrition and cancer clinical trials. Cancer, 58, 1378-1386.
22. Thompson SG. (1994) Why sources of heterogeneity in meta-analysis should be investigated. British Medical Journal, 309, 1351-1355.
23. Messori A, Rampazzo R. (1993) Meta-analysis of clinical trials based on censored end-points: simplified theory and implementation of the statistical algorithms on a microcomputer. Computer Methods and Programs in Biomedicine, 40, 261-267.
24. Fine HA, Dear KBG, Loeffler JS, Black PML. Canellos GP. (1993) Meta-Analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71, 2585-2592.